588 Results found
Articles
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review
Abstract Background: Galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), has demonstrated clinical benefit as a preventive treatment of episodic cluster headache (ECH) but not in chronic cluster headache (CCH) to this date....
Published:
November 3, 2022Addressing inequities in headache care by embedding services in a community health center in Boston, MA
Abstract There is a critical need to diagnose and treat headache disorders in primary care settings. This is especially true for those who face systemic barriers to healthcare access due to racism or poverty....
Published:
November 3, 2022The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition
No abstract available Keywords: 3rd edition; International Classification of Headache Disorders; chronic migraine; definition; high frequency episodic migraine.
Published:
October 27, 2022Narrative review of peripheral nerve blocks for the management of headache
Abstract Objective: To provide an overview of the current available literature on peripheral nerve blocks for the management of migraine and other headache disorders in adults. Background: Peripheral nerve blocks have been commonly performed...
Published:
October 27, 2022Digital headache self-management interventions for patients with a primary headache disorder: A systematic review of randomized controlled trials
Abstract Objective: This article systematically reviews the empirical literature examining the efficacy of digital headache management interventions for patients with a primary headache disorder. Background: Digital headache management interventions provide opportunities to improve access...
Published:
October 27, 2022A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension
Abstract Objective: To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in patients aged 6 to 11 years. Background: Triptans have demonstrated efficacy in adults,...
Published:
October 27, 2022Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial
Abstract Objective: Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine. Background: Calcitonin gene-related peptide-targeting agents are a novel class of therapeutics for migraine, but none are...
Published:
October 20, 2022Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
Abstract Objective: This prospective cohort, real-life study aimed to evaluate whether galcanezumab, a monoclonal antibody anti-calcitonin gene-related peptide (CGRP) ligand, can reduce caregivers’ distress and improve their mutuality with patients. Background: Migraine is a...
Published:
October 13, 2022Headache and acute cerebrovascular disease: How do we differentiate primary and secondary headache disorders in the emergency setting?
No abstract available Keywords: acute cerebrovascular disease; emergency department; headache; ischemic stroke; missed diagnosis.
Published:
October 13, 2022A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond
Abstract Objective: To summarize the pharmacology of the calcitonin peptide family of receptors and explore their relationship to migraine and current migraine therapies. Background: Therapeutics that dampen calcitonin gene-related peptide (CGRP) signaling are now...
Published:
October 13, 2022Off-label use of lacosamide, an alternative for the treatment of neuropathic pain
No abstract available
Published:
October 13, 2022Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle
Abstract Background: Treatment wearing-off has been reported for calcitonin gene-related peptide-pathway monoclonal antibodies, including erenumab, specifically in the last week of the monthly dosing cycle. Objective: We sought to determine the consistency of erenumab...
Published:
October 13, 2022Migraine and infertility, merging concepts in women’s reproductive health: A narrative review
Abstract Objective: The objective is to examine issues around treating infertility in patients with migraine. Background: Women outnumber men in migraine diagnosis with a 3:1 ratio; the disease is commonly expressed in women of...
Published:
October 6, 2022The teaching of headache medicine in France: A questionnaire-based study
Abstract Background: The treatment of patients with headache represents an important part of a neurologist’s activity. It requires sufficient training for neurology residents. In France, residents in neurology can complete this training by attending...
Published:
October 6, 2022Gestational exposure to erenumab-The outcome of three pregnancies
Abstract Erenumab is a monoclonal antibody (mAb) approved for the preventive treatment of migraine. While preclinical studies on calcitonin gene-related peptide mAbs did not identify any reproductive toxicity, pregnant and breastfeeding women were excluded...
Published:
September 29, 2022The elephant in the room: How the underfunding of headache research stunts the field
No abstract available Keywords: National Institutes of Health; funding; headache; migraine.
Published:
September 29, 2022A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
Abstract Objective: To compare effects of an initial dose of calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) antagonists on gastrointestinal (GI) motility in patients with migraine and to explore if the mechanistic difference contributes...
Published:
September 22, 2022Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants
Abstract Objective: This study looked at differences in the presence of headache as an onset symptom of coronavirus disease 2019 (COVID-19) and as a post-COVID-19 symptom in individuals previously hospitalized owing to infection with...
Published:
September 22, 2022A non-oral gepant for acute treatment of migraine
No abstract available Keywords: acute treatment; gepant; migraine; non-oral treatment; treatment gap.
Published:
September 22, 2022Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies
Abstract Objective: This narrative review of the literature concerns persistent headache attributed to past non-traumatic subarachnoid hemorrhage (SAH), based off demographic and clinical features, what are pathophysiologic mechanisms by which these headaches occur, which...
Published:
September 22, 2022
